Gerbasi ME, Goss D, Petrillo J, Nejati M, Lewis S. Patient experiences in essential tremor: mapping functional impacts to existing measures using qualitative research. Poster presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders; August 27, 2023. Copenhagen, Denmark. [abstract] Mov Disord. 2023; 38(Suppl 1).
Serbin M, Sutphin J, Leach C, Mansfield C, Yonan C, Klepitskaya O, Sheehan M, Donnelly A. Evaluating patients' preferences for parkinson's disease treatments. Poster presented at the MDS Virtual Congress 2021; September 17, 2021. [abstract] Mov Disord. 2021 Sep; 36(S1).
Serbin M, Odak S, Macahilig C, Joshi N, Shah A, Ng X, Olson K, Liang G, Klepitskaya O, Yonan C. Motor fluctuations in a real‐world sample of patients with parkinson's disease. Poster presented at the MDS Virtual Congress 2020; September 2020. [abstract] Mov Disord. 2020 Sep 11; 35(Suppl 1):S142. doi: 10.1002/mds.28268
Serbin M, Odak S, Macahilig C, Joshi N, Shah A, Ng X, Olson K, Liang G, Klepitskaya O, Yonan C. Real-world healthcare resource utilization in patients with parkinson's disease and motor fluctuations. Poster presented at the 2020 MDS Virtual Congress; September 2020. [abstract] Mov Disord. 2020 Sep; 35(Suppl 1):S142.
Thach A, Sutphin J, Coulter J, Mansfield C. A discrete-choice experiment evaluating preferences for on-demand treatments for patients with Parkinson's Disease and “OFF” episodes. Poster presented at the MDS Virtual Congress 2020; September 11, 2020. [abstract] Mov Disord. 2020 Sep; 35(S1):S427. doi: 10.1002/mds.28268
Thach A, Coulter J, Leach C, Sutphin J, Mansfield C. On-demand treatment preferences of patients with Parkinson's Disease and “OFF” episodes: heterogeneity across patient subgroups. Poster presented at the MDS Virtual Congress 2020; September 11, 2020. [abstract] Mov Disord. 2020 Sep; 35(S1):S427-8. doi: 10.1002/mds.28268
Barnett C, Davenport MS, Montgomery JS, Kunju LP, Denton B, Piert M. 18F-choline PET/mpMRI for detection of significant prostate cancer, part 2: cost-effectiveness analysis. J Nucl Med. 2019 Dec;60(12):1705-12. doi: 10.2967/jnumed.119.225771
Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shanka PR, Rajendiran T, Shao X, Lee E, Barnett CL, Denton BT, Piert M. 18F-choline PET/mpMRI for detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies. J Nucl Med. 2019 Aug 16. doi: 10.2967/jnumed.119.225789.
Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474-80.
Edin HM, DiBenedetti D, Hill CD. Adherence among patients with Parkinson's Disease taking ropinirole immediate release at least three times daily. Poster presented at the Movement Disorders Society; June 13, 2008. [abstract] Mov Disord. 2008; 23:S344-5.
Hagell P, Whalley D, McKenna SP, Lindvall 0. Health status measurement in Parkinson's disease: validity of the PDQ-39 and Nottingham Health Profile. Mov Disord. 2003 Jul 1;18(7):773-83.